Brief: Mabion Signs Framework Deal With UK Pharmaceutical Company
21/10/2024 15:42
Oct 21 (Reuters) - Mabion SA MABP.WA :
* SIGNS FRAMEWORK AGREEMENT WITH UK PHARMACEUTICAL COMPANY
* AGREEMENT INCLUDES GMP PROCESS DEVELOPMENT AND QUALITY
CONTROL
* AGREEMENT TERM IS 5 YEARS FROM SIGNING DATE
Source text for Workspace: ID:nEM9Gm1H1a
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys